COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future
Overview
Authors
Affiliations
Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include comorbidities, uncontrolled disease, and current line of treatment. Although COVID-19 vaccines have afforded some level of protection against infection and severe disease among patients with solid tumors and hematologic malignancies, decreased immunogenicity and real-world effectiveness have been observed among this population compared with healthy individuals. Characterizing and understanding the immune response to increasing doses or differing schedules of COVID-19 vaccines among patients with cancer is important to inform clinical and public health practices. In this article, we review SARS-CoV-2 susceptibility and immune responses to COVID-19 vaccination in patients with solid tumors, hematologic malignancies, and those receiving hematopoietic stem cell transplant or chimeric-antigen receptor T-cell therapy.
Cai Z, Zou D, Ma Q, Sun W, Guo Y SAGE Open Med Case Rep. 2025; 13:2050313X241306236.
PMID: 40078172 PMC: 11898238. DOI: 10.1177/2050313X241306236.
Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P EBioMedicine. 2024; 109:105385.
PMID: 39395230 PMC: 11663764. DOI: 10.1016/j.ebiom.2024.105385.
Deng X, Jiang Y, Chen W, Qin X, Chen J, Li H Transl Cancer Res. 2024; 13(8):4219-4230.
PMID: 39262461 PMC: 11384919. DOI: 10.21037/tcr-24-70.
Wu L, Yang L, Qian X, Hu W, Wang S, Yan J J Funct Biomater. 2024; 15(8).
PMID: 39194667 PMC: 11355305. DOI: 10.3390/jfb15080229.
COVID-19 vaccine updates for people under different conditions.
Huang Y, Wang W, Liu Y, Wang Z, Cao B Sci China Life Sci. 2024; 67(11):2323-2343.
PMID: 39083202 DOI: 10.1007/s11427-024-2643-1.